Figure 2.

TGMS-TAC administration prolongs graft survival. (A) Kaplan-Meier survival curve of the three different groups (n = 4/group): untreated, TGMS-TAC single administration, and TGMS-TAC multiple administration (TGMS-TAC (R)). **p<0.01, ****p<0.0001 calculated by Log-rank (Mantel-Cox) test. (B) Macroscopic evaluation of graft survival during follow-up was graded as follows: 0 = no difference between graft skin and native skin, I = mild erythema, II = moderate erythema with the beginning of scaling and scabbing, III = severe erythema and scabbing with areas of epidermolysis, IV = full-thickness graft epidermolysis with areas of necrosis. Animals 5–8 were euthanized when reaching grade IV rejection at POD 35, 39, 51, and 60, respectively. A syringe indicates the time points of TGMS-TAC injection (C) Representative images of graft changes at endpoint (macroscopic grade IV rejection or POD90) with their corresponding grading. (D) Representative histological H&E staining of graft skin and muscle samples collected at endpoint. Skin was scored according to the Banff 2007 working classification. Muscle changes were graded as 0 = none, 1 = minimal, 2 = moderate, and 3 = extensive damage.